Background: Few published data are available on the morbidity and mortality of bloodstream infections (BSIs) in Japan. We sought to investigate the epidemiology of BSIs, the involvement of antimicrobial resistance, and the factors that influence patient prognosis. Methods: This single-center study retrospectively evaluated patients who were found to have positive blood cultures at a tertiary teaching hospital between January 2012 and December 2016. Results: A total of 2,105 patients with BSIs were included; 1,786 survived and 319 died, and the 30-day mortality rate was 15.2% over the 5-year study period. BSIs caused by yeasts were independently associated with 30-day mortality. The 30-day mortality rate of BSIs caused by extended-spectrum beta lactamaseÀproducing gram-negative bacteria was significantly higher than that of BSIs caused by nonproducing bacteria. Discussion: The differences in mortality may be caused by differences in the distribution of pathogens and in the delivery of health care. Conclusions: This study reported epidemiology and antimicrobial resistance data of BSIs in Japan and identified several risk factors associated with 30-day mortality. National surveillance of BSIs is required in Japan for comparison with other countries.
Bloodstream infections (BSIs) have high morbidity worldwide [1] [2] [3] [4] and an estimated overall crude mortality rate of 15%-30%. 1, [5] [6] [7] Antimicrobial resistance(AMR)isaseriousproblem,particularlyforextended-spectrum beta lactamase (ESBL)Àproducing Escherichia coli and Klebsiella species 1, 7 and carbapenem-resistant Enterobacteriaceae (CRE). 8 Only 2 reports of epidemiology of BSIs have been published in Japan; however, they lack datarelatedtomicrobiologicstudies,patientcomorbidities,andBSIseverity. 1, 9 A previous study has reported that the incidence of BSI attributable to ESBL-producing E coli and Klebsiella species increased from 2008 to 2012 in Japanese university hospitals. 1 A more complete understanding of BSIs in Japan is important not only for treatment but also for rational implementation of antimicrobial stewardship programs. 10 The study aimed to describe the epidemiology of BSIs, including the involvement of AMRanditsimpactonpatientprognosis.
METHODS

Study design and data collection
This single-center, retrospective study was performed at the Showa University Hospital, a 1,014-bed tertiary teaching hospital, in Japan and included all the patients with positive blood culture results during a 5-year interval from January 1, 2012, to December 31, 2016. Patient age, sex, place of onset (hospital-acquired or community-acquired infection), length of stay, mortality, Charlson Comorbidity Index (CCI), 11 quick sep-outcometo a groupthat survived for atleast 30 days (survival group)and a group that died within 30 days (death group) of the blood culture. Hospital-acquiredinfectionwasdefinedasapositivebloodcultureat2daysafter hospitaladmission;allothercaseswereclassifiedascommunity-acquired infection. 15 Polymicrobial infection was defined as the isolation of more than1microbialspeciesduringasingleBSIepisode.
Microbiologic results of blood culture
BSIs were defined as the isolation of the organism from 1 or more positive blood cultures. Isolation of skin-resident or environmental bacteria from 2 or more blood cultures or a blood culture plus an intravascular catheter, cerebrospinal fluid, bile, or abscess sample other than sputum and urine were included. 16, 17 For patients with repeated positive blood cultures within 1 year (including cases of readmission), only the first BSI episode was considered. Blood cultures were performed with BD BACTEC FX System (Becton, Dickinson and Company, Franklin Lakes, NJ). All strains were screened using a MicroScan WalkAway system (Beckman Coulter, Inc., Tokyo, Japan).
AMR definition
AMR was tested in 7 microorganisms: Staphylococcus aureus, E coli, Klebsiella species,Enterobacterspecies, Serratiaspecies, Pseudomonas species, and Acinetobacterspecies.BecauseESBL-producingisolateswerecollected in only 1 case, Proteus species were excluded from the analysis. The clinical breakpoints of the Clinical and Laboratory Standards Institute were used to define AMR. 18 Multidrug-resistant Pseudomonas aeruginosa strains were resistant to at least 3 of the following antimicrobial agents: piperacillinandtazobactam,ceftazidime,fluoroquinolones(ciprofloxacin or levofloxacin), aminoglycosides (gentamicin or amikacin), andcarbapenems (imipenem or meropenem). 19 Multidrug-resistant Acinetobacter species were resistant to fluoroquinolones, aminoglycosides, and carbapenems. 19 Methicillin resistance in S aureus was confirmed via oxacillin and cefoxitin testing using the broth microdilution method. ESBL production was determined by the double disc synergy test. Discs containing cephalosporins(ceftazidimeandcefotaxime)wereappliednexttoamoxicillin-clavulanic acid discs. 20 Metallo-beta-lactamase (MBL) production was determined by screening with a sodium mercaptoacetic acid disc and a disc containing imipenem and ceftazidime. 21 CRE was defined by both the Clinical and Laboratory Standards Institute criteria and the Japanese criteria that include isolation and identification of Enterobacteriaceaeand a minimum inhibitory concentration of meropenem 2 mg/mL or minimum inhibitory concentrations of imipenem 2 mg/mL and cefmetazole 64 mg/mL. 22 The 30-day mortality rates of 5 antimicrobial-resistant infections, methicillin-resistant S aureus (MRSA), ESBL-producing bacteria, carbapenem-resistant P aeruginosa, CRE, and MBL-producing bacteria werecomparedwiththe30-daymortalityratesofthecorrespondingnonAMRinfections.
Statistical analysis
Pearson'schi-squareorFisher'sexacttestwasusedtocomparethecategorical variables, and the Student test was used to compare the continuous variables. All the statistical tests were 2-tailed, and P < .05 was considered significant. Bonferroni correction was used to compare the annual BSI mortality rates. The significance level wasset at P < .0125. Multiple logistic regression analysis was performed to identify factors significantly associated with all-cause 30-day mortality. All variables in the univariate analyses were included in a multivariate analysis of independent association with 30-day mortality with the calculation of adjusted odds ratios (ORs). Spearman's rank correlation analysis was used to assess multicollinearity. Statistical analysis was performed with SPSS statistics version 24.0(IBM Japan, Tokyo, Japan).
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RESULTS
Clinical characteristics of the study population
During the 5-year study period, 4,464 cases of positive blood cultures were identified. After excluding 1,862 duplicated cultures and 497 contaminated cultures 2,105 patients with episodes of BSI, 1,786 survivors, and 319 deaths, were included in the analysis (Fig 1) . Table  1 shows the patient characteristics. The in-hospital mortality rate was 22.6% (475/2,105), the 30-day mortality rate was 15.2% (319/ 2,105), and the 7-day mortality rate was 6.7% (141/2,105). Appendix Table A shows the annual BSI mortality. Table 2 shows the microorganisms isolated from the patients with BSI. E coli was the most frequent pathogen, followed by S aureus and Streptococcus species. The most frequently isolated AMR pathogens were carbapenem-and fluoroquinolone-resistant Pseudomonas species, MRSA, ESBL, and fluoroquinolone-resistant E coli. The mortality rate was high in patients with yeast and polymicrobial infections. Table 3 shows the results of multiple logistic regression analysis of 30-day mortality. Multivariate analysis found that age 65 years, hospital-acquired infection, qSOFA, SOFA score, CCI, CRBSI, urinary tract infection, BSI-caused Streptococcus species, E coli or yeasts, and surgery were significantly associated with 30-day mortality.
Microbiology and AMR
Predictors of 30-day mortality
Risk for 30-day mortality of each antimicrobial-resistant microorganism Figure 2 is a Forest plot showing the risk of 30-day mortality attributed to infection with antimicrobial-resistant microorganisms. BSIs caused by ESBL-producing gram-negative bacteria had significantly higher mortality rates than those caused by nonproducing bacteria (OR, 2.552; 95% confidence interval [CI]: 1.297À5.019; P value = .005]. BSIs caused by MRSA, carbapenemresistant P aeruginosa, CRE, of MBL-producing bacteria had higher NOTE. Data are presented as n (%). CLSI, Clinical and Laboratory Standards Institute; ESBL, extended-spectrum beta lactamase; MDRAB, multidrug resistant Acinetobacter species; MDRP, multidrug-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus. *MDRP is defined as the resistance combinations among isolates tested against at least 3 antimicrobial groups among piperacillin and tazobactam, ceftazidime, fluoroquinolones, aminoglycosides, and carbapenems. y MDRAB is defined as the resistance combinations among isolates tested to fluoroquinolones, aminoglycosides, and carbapenems.
30-day mortality rates than infections caused by nonproducing bacteria; however, the differences were not statistically significant.
DISCUSSION
To our knowledge, this is the first study to report the epidemiology of BSIs in Japan, including the involvement of AMR microorganisms, patient comorbidities, and severity of illness scores (eg, CCI, qSOFA, and SOFA score). The 30-day and in-hospital mortality rates were estimated as 15.2% and 22.6%, respectively. Previous studies have reported a 30-day mortality rate of 19.3% for hospital-acquired BSIs. 9 The overall crude mortality rate of nosocomial BSIs in Japan is estimated as 24.5%. 1 Comparisons are difficult because previous studies did not consider severity of illness scores and AMR testing. Coordinated, nationwide BSI surveillance in Japan is needed for comparison of clinical indicators.
Mortality estimates vary with country, and overall in-hospital mortality has been estimated as 15.3% in Ireland, 5 40.0% in Brazil, 23 and 28.9% in Vietnam. 7 The differences in mortality rates may be caused by differences in the distribution of pathogens and in the delivery of health care. The prevalence of AMR in Enterobacteriaceae was higher in Brazil 23 and Vietnam 7 than in other countries, and fungal BSIs were a significant contributor to mortality in some reports. 3, 23, 24 Multivariate analysis in this study found that fungal BSIs were independently associated with 30-day mortality. Fungal BSIs are life threatening for immunocompromised and critically ill patients, such as those with malignancies, ongoing cancer chemotherapy, and organ transplants. In addition, the use of intravenous catheters increases the risk of fungal BSIs. The prompt initiation of antifungal therapy is crucial for these patients, but blood cultures for fungal detection take several days, making early diagnosis difficult. 25 These factors may help explain the increased risk of mortality in fungal BSIs. Episodes of BSI with a strong suspicion of coagulase-negative staphylococci, Bacillus species, Corynebacterium species, and Cutibacterium species as a cause were included in the analysis. Most BSIs associated with those bacteria occurred in patients with intravenous catheters or hematologic malignancies. Many previous studies excluded BSIs with culture isolates of skin-resident and environmental bacteria, 1, 4, 5 because it is difficult to distinguish infecting from contaminating microorganisms. Because of possible influence on incidence and mortality estimates, comparison with BSI studies not including those bacteria should be made with caution.
In this study, community-acquired BSIs had a low mortality risk, consistent with previous reports that most of BSIs caused by E coli occurred in the community setting and were not fatal cases. 26, 27 BSIs caused by E coli and Klebsiella species had relatively low 30-day mortality, ESBL-producing isolates were associated with a significantly increased 30-day mortality. In addition, the 30-day mortality rate of carbapenem-resistant gram-negative bacteria was high. Particularly, we observed a high prevalence of carbapenem-resistant Pseudomonas species compared with that observed in other countries. 3, 23 The results suggest that AMR has a poor prognosis in BSIs; however, the number of antimicrobial-resistant isolates was too small to test the significance of any influence of AMR on prognosis. Further study is needed to investigate the effect of AMR on patient prognosis. The limitations of this study include its retrospective design and conduct at a single center in Tokyo. The results may not be representative of other regions of Japan with different distributions of AMR. However, there are no aggregated national data in Japan. This investigation provides valuable data as a pilot study for national surveillance and potential comparison with data from other countries. Second, rapid diagnostic testing (eg, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry) is not available at our institution. Rapid identification of pathogens affects prognosis; however, few institutions in Japan have access to such technologies. Finally, some of the AMR data were obtained with screening tests (eg, double disc synergy test) and thus include resistance conferred by AmpC beta-lactamases and various carbapenemases and other causes that we could not identify. Additional molecular analysis of resistance mechanisms is needed to clarify the relation of AMR and patient prognosis in BSIs.
In conclusion, the epidemiologic and AMR data of BSIs in Japan identified several risk factors associated with 30-day mortality of BSIs. Infection prevention and antimicrobial stewardship programs in Japanese health care facilities should consider the high overall attributable mortality of BSI, as well as that of the individual organisms and their resistant strains. Strategic planning and implementation of BSI surveillance is required in Japan.
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